315,338 Shares in IQVIA Holdings Inc. $IQV Bought by Hsbc Holdings PLC

Hsbc Holdings PLC purchased a new stake in shares of IQVIA Holdings Inc. (NYSE:IQV) during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 315,338 shares of the medical research company’s stock, valued at approximately $60,904,000.

Other hedge funds have also recently added to or reduced their stakes in the company. EFG International AG purchased a new position in shares of IQVIA in the 2nd quarter worth about $491,000. Redwood Grove Capital LLC bought a new stake in IQVIA in the 2nd quarter worth approximately $18,066,000. Primecap Management Co. CA bought a new stake in IQVIA in the 2nd quarter worth approximately $7,142,000. Canada Pension Plan Investment Board purchased a new stake in IQVIA in the second quarter worth approximately $240,911,000. Finally, Parkman Healthcare Partners LLC bought a new position in IQVIA during the second quarter valued at approximately $20,445,000. Institutional investors own 89.62% of the company’s stock.

Insider Activity

In related news, insider Keriann Cherofsky sold 558 shares of the business’s stock in a transaction dated Wednesday, July 29th. The stock was sold at an average price of $245.21, for a total transaction of $136,827.18. Following the transaction, the insider owned 2,989 shares in the company, valued at $732,932.69. The trade was a 15.73% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Bhavik Patel sold 1,855 shares of the company’s stock in a transaction that occurred on Friday, July 31st. The shares were sold at an average price of $235.27, for a total value of $436,425.85. Following the transaction, the insider directly owned 1,348 shares of the company’s stock, valued at $317,143.96. The trade was a 57.91% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 12,913 shares of company stock valued at $3,098,793. 1.70% of the stock is currently owned by insiders.

Analysts Set New Price Targets

IQV has been the subject of a number of recent research reports. William Blair upgraded shares of IQVIA to a “strong-buy” rating in a report on Tuesday, July 28th. JPMorgan Chase & Co. lifted their target price on shares of IQVIA from $225.00 to $285.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 29th. Mizuho boosted their price target on shares of IQVIA from $215.00 to $230.00 and gave the stock an “outperform” rating in a research note on Monday, July 13th. HSBC restated a “buy” rating and set a $240.00 price target on shares of IQVIA in a research report on Monday, July 6th. Finally, Stifel Nicolaus lifted their price objective on IQVIA from $220.00 to $276.00 and gave the stock a “buy” rating in a report on Wednesday, July 29th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $241.88.

IQVIA Stock Up 0.8%

Shares of IQVIA stock opened at $261.57 on Thursday. The company has a debt-to-equity ratio of 2.18, a quick ratio of 0.71 and a current ratio of 0.71. IQVIA Holdings Inc. has a 52-week low of $154.50 and a 52-week high of $262.51. The company’s 50 day moving average price is $218.41 and its 200-day moving average price is $188.59. The stock has a market capitalization of $43.05 billion, a price-to-earnings ratio of 32.45, a P/E/G ratio of 2.22 and a beta of 1.18.

IQVIA (NYSE:IQV) last posted its quarterly earnings results on Tuesday, July 28th. The medical research company reported $3.15 EPS for the quarter, beating analysts’ consensus estimates of $3.03 by $0.12. The company had revenue of $4.37 billion during the quarter, compared to analyst estimates of $4.30 billion. IQVIA had a net margin of 8.10% and a return on equity of 30.25%. The firm’s revenue was up 8.7% compared to the same quarter last year. During the same period in the prior year, the business posted $2.81 EPS. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. Equities research analysts forecast that IQVIA Holdings Inc. will post 11.57 EPS for the current year.

IQVIA announced that its Board of Directors has approved a share repurchase program on Thursday, May 7th that allows the company to repurchase $2.00 billion in shares. This repurchase authorization allows the medical research company to buy up to 6.8% of its shares through open market purchases. Shares repurchase programs are usually a sign that the company’s leadership believes its stock is undervalued.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.